Research Progress of Treg/Th17 in the Treatment of Chronic Obstructive Pulmonary Disease with Lung Cancer.
10.3779/j.issn.1009-3419.2019.12.10
- Author:
Jinhua ZHOU
1
;
Wei WANG
2
;
Ruijuan LIU
1
Author Information
1. Jining No.1 People's Hospital, Jining 272000, China.
2. The Second Hospital of Shandong University, Jinan, 250033, China.
- Publication Type:Journal Article
- Keywords:
Chronic obstructive pulmonary disease;
Lung neoplasms;
Th17;
Treg;
Tumor microenvironment;
immunization
- From:
Chinese Journal of Lung Cancer
2019;22(12):794-797
- CountryChina
- Language:Chinese
-
Abstract:
Chronic obstructive pulmonary disease (COPD) and lung cancer are global high incidence and high mortality diseases, which seriously increase the socio-economic burden. Smoke exposure, genetic susceptibility and chronic inflammation are common susceptible factors. At present, abnormal inflammatory immune response plays an important role in the occurrence and development of the two diseases. In the process of immune response, tumor microenvironment (TME) is gradually produced, which is beneficial to angiogenesis and immunosuppression, and finally leads to immune escape of tumor cells, leading to tumor formation. In this paper, the present situation of COPD complicated with lung cancer and the relationship between abnormal immune response, especially Treg/Th17, and its occurrence and development are briefly reviewed.
